Drugs / DT5aP-IPV-Hib 5-component Pertussis vaccine
DT5aP-IPV-Hib 5-component Pertussis vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00355654 | Sep 2006 → Sep 2007 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00287092 | Feb 2006 → May 2007 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DT5aP-IPV-Hib 5-component Pertussis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00355654 ↗ |
| Modality | Vaccine | “DT5aP-IPV-Hib 5-component Pertussis vaccine” NCT00287092 ↗ |
| Route | Intramuscular | “0.5 mL, IM” NCT00287092 ↗ |